Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620759 · ClinicalTrials.gov registry record · Phase 2
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
A Phase 2 study of Major Depressive Disorder and Alcohol Use Disorder, sponsored by Johns Hopkins University.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT04620759: Active Phase 2 study of Major Depressive Disorder and Alcohol Use Disorder, sponsored by Johns Hopkins University.
NCT04620759 is a Phase 2 study of Major Depressive Disorder and Alcohol Use Disorder that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 90 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04620759, a Phase 2 study of Major Depressive Disorder and Alcohol Use Disorder, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
Primary Outcome
The GRID-Hamilton Depression Rating Scale is a 17-item clinician-administered rating scale designed to assess severity of depressive symptoms. The score range for the GRID-HAMD is 0 to 52, with higher score indicating more severe depression.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Psilocybin
Study Locations (1)
Maryland
- Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 2 |
What the registry record for NCT04620759 still lists
NCT04620759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04620759 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04620759 about?
NCT04620759 is a clinical study titled "Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder". The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
What is the current status of trial NCT04620759?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2021-04-14. Estimated completion is 2027-03-30.
What conditions does trial NCT04620759 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Alcohol Use Disorder.
What interventions are being tested in trial NCT04620759?
The interventions under investigation include: Placebo (DRUG), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT04620759?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04620759 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04620759's enrollment target sits among peer trials
90 139th of 282 higher than 143 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI